Company Overview of Sequella, Inc.
Sequella, Inc., a clinical stage biopharmaceutical company, develops and commercializes treatment products for diagnosis and treatment of infectious diseases. The company’s products include TB Patch, a point-of-care diagnostic used to diagnose active tuberculosis (TB) infection; SQ109, a molecule anti-TB drug; drug compliance monitor, a medical device that records when medication is taken; SQ609, an antibiotic compound for vitro and in vivo anti-TB activities; and SQ641, a natural product for the treatment of TB or bacterial pneumonia. Sequella, Inc. was founded in 1997 and is based in Rockville, Maryland.
9610 Medical Center Drive
Rockville, MD 20850
Founded in 1997
Key Executives for Sequella, Inc.
Executive Vice President of Corporate Development
Vice President of Drug Discovery
Compensation as of Fiscal Year 2014.
Sequella, Inc. Key Developments
Sequella, Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 03:40 PM
Sep 25 13
Sequella, Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 03:40 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Carol A. Nacy, Co-Founder, Chairman and Chief Executive Officer.
Sequella Seeks Financing
Jul 17 13
Sequella, Inc. plans to raise $38 million to pay for clinical trials — almost twice its previous fundraising target. Sequella announced it had snapped up the rights to Pfizer Inc.'s tuberculosis antibiotic, called sutezolid which expands that funding need. "Most big pharma, including Pfizer, are moving out of antibiotics/anti-infective drugs. Small biotech is taking over on the R&D. I think that's very important, because we're facing a crisis in MDR infections worldwide, including in the U.S," said Sequella, Chief Executive Officer, Carol Nacy.
Sequella Inc. Licenses its B-Smart(TM) Technology to Laboratory Corporation of America Holdings
Oct 22 12
Sequella Inc. licensed its B-SMART(TM) technology to Laboratory Corporation of America(R) Holdings to allow LabCorp to develop a new laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis and to commercially use the assay in the United States. The assays that LabCorp will develop using B-SMART(TM) technology will combine nucleic acid testing with phage-based technology to accurately and quickly identify any resistance of M. tuberculosis clinical isolates to antitubercular antibiotics, regardless of whether the resistance genotype is known. Sequella retains all rights to commercialize B-SMART(TM) technology worldwide for indications other than tuberculosis, and for territories other than the United States for tuberculosis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|